MBX shares are currently trading at $28.67, with analysts maintaining a Strong Buy consensus and a high target of $80, according to InvestingPro data. The price target increase comes after MBX’s ...

Fintel reports that on December 19, 2025, Stifel maintained coverage of MBX Biosciences (NasdaqGS:MBX) with a Buy recommendation. Analyst Price Forecast Suggests 108.57% Upside As of December 6, 2025, ...

MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key ...

In recent months, MBX Biosciences reported positive topline Phase 2 results for its lead drug canvuparatide in hypoparathyroidism and completed an upsized US$200,000,000 capital raise, while ...

MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and ...

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) rose sharply in pre-market trading after the company announced that it will provide topline results from its Phase 2 clinical trial of potential ...

MBX Biosciences Inc. posted positive top-line phase II study data in treating chronic hypoparathyroidism, positioning itself to take on a U.S. FDA-approved therapy for the rare endocrine disease.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

MBX Biosciences, Inc. (NASDAQ:MBX) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase ...